,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['trastuzumab']
db04 data presented by dr. modi. trastuzumab deruxtecan in her2 low (1+ or 2+), er+ or - doubled median pfs and improved os &gt;6 months in this pre-treated population with median 3 prior lines of therapy. #asco22 
Oncologist & researcher at Memorial Sloan Kettering Cancer Center. Working on optimizing lifestyle & metabolic health to improve cancer risk and outcomes.